DeNoble V J, Jones K W, Schaeffer C L, Bauerle L M
E.I. du Pont de Nemours & Co., Inc., Medical Products Department, Wilmington, DE 19880-0400.
Eur J Pharmacol. 1990 Jan 10;175(2):197-202. doi: 10.1016/0014-2999(90)90230-4.
3-((+-)-2-Carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP), phencyclidine (PCP) and diazepam were evaluated for their ability to produce a deficit for a single trial step-through passive avoidance response in rats. Pretraining administration with CPP at doses ranging from 2.0 to 10.0 mg/kg s.c. significantly decreased retention latencies 24 h after passive avoidance training. Similar effects were found with PCP at doses ranging from 0.5 to 1.7 mg/kg s.c. and diazepam at doses between 5.0-18.0 mg/kg s.c. Pretraining administration with the benzodiazepine antagonist, RO15-1788 at doses between 0.1-15 mg/kg s.c., did not alter retention latencies. Co-administration of RO15-1788 (0.01-15.0 mg/kg s.c.) with CPP (6.0 mg/kg s.c.) or PCP (1.0 mg/kg s.c.) failed to block decreases in latencies. However, when RO15-1788 was co-administered with diazepam (9.0 mg/kg s.c.) a dose-related antagonism of diazepam's effects were found. These results suggest that the behavioral actions of CPP and PCP on passive avoidance retention are not mediated via the benzodiazepine receptor complex.
对3-((±)-2-羧基哌嗪-4-基)丙基-1-膦酸(CPP)、苯环己哌啶(PCP)和地西泮在大鼠单次试验穿梭箱被动回避反应中产生缺陷的能力进行了评估。在被动回避训练前皮下注射剂量范围为2.0至10.0mg/kg的CPP,显著缩短了被动回避训练24小时后的记忆潜伏期。在皮下注射剂量范围为0.5至1.7mg/kg的PCP和皮下注射剂量在5.0 - 18.0mg/kg的地西泮中也发现了类似的效果。在皮下注射剂量范围为0.1至15mg/kg的苯二氮䓬拮抗剂RO15 - 1788进行预训练给药,并未改变记忆潜伏期。将RO15 - 1788(0.01 - 15.0mg/kg皮下注射)与CPP(6.0mg/kg皮下注射)或PCP(1.0mg/kg皮下注射)联合给药,未能阻止潜伏期的缩短。然而,当RO15 - 1788与地西泮(9.0mg/kg皮下注射)联合给药时,发现了与剂量相关的地西泮效应拮抗作用。这些结果表明,CPP和PCP对被动回避记忆的行为作用不是通过苯二氮䓬受体复合物介导的。